Proof-of-concept trial: A Transglutaminase 2 inhibitor attenuated gluten-induced duodenal mucosal damage in patients with celiac disease.
5 Jul, 2021 | 01:56h | UTCCommentary: NEJM: First Effective Non-Dietary Treatment Of Celiac Disease – MedicalResearch